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Background: Photodynamic therapy (PDT) is considered as a possible alternative approach to overcoming multidrug resistance 
(MDR). Analysis of cross-resistance to PDT in cells with different MDR pathways and resistance levels seems to be advantageous 
for elucidating the general mechanisms of cancer cell resistance to various treatment modalities. Aim: The aim of the study was 
to clarify whether the Jurkat/A4 leukemia cells with MDR phenotype are cross-resistant to PDT. Methods: Human T-cell acute 
lymphoblastic leukemia line Jurkat and Jurkat/A4 subline with MDR phenotype were used. 5-Aminolevulinic acid (ALA) and 
Photolon (a complex of chlorine-e6 and polyvinylpyrrolidone; PL) or gold nanocomposite of PL were applied as photosensitizers. 
The cells were pretreated with photosensitizers and exposed to laser radiation at corresponding wavelengths. The phototoxicity 
was assessed in trypan blue exclusion test. The hypodiploid cell fraction was analyzed by flow cytometry of propidium iodide-stained 
cells. Expression of genes related to PDT resistance was analyzed by microarray technique with Affymetrix U133A chips. Results: 
ALA-mediated PDT resulted in dose-dependent cell death in both lines, the relative photodynamic efficacy in Jurkat/A4 cells be-
ing inferior to that in the parental Jurkat cells. There was no correlation between phototoxicity and apoptosis induction both 
in Jurkat and Jurkat/A4 cells. PL-mediated general phototoxicity in Jurkat cells amounted up to 75% at the maximal photosen-
sitizer dose with about 40% of apoptotic death fraction. PL-phototoxicity in Jurkat/A4 cells was considerably lower. In contrast 
to Jurkat cells, PL-gold composite did not increase the efficacy of photosensitization as compared to free PL in Jurkat/A4 cells. 
Conclusions: Multidrug-resistant Jurkat/A4 cells exhibit reduced sensitivity to phototoxic effect in comparison with parental 
Jurkat cells independently of nature of the photosensitizer being assayed.
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Multidrug resistance (MDR) is one of the main 
problems limiting the efficacy of cancer chemotherapy. 
The predominant MDR mechanism is associated with 
the overexpression of certain transmembrane proteins 
such as P-glycoprotein (P-gp) and other members 
of ABC transporter family providing for the increased 
efflux of chemotherapeutics out of cancer cells. 
Several approaches seem to be useful in overco-
ming MDR phenotype. Among them are the design 
of chemotherapeutic agents with low affinity to ABC 
transporters, the target therapy, and the use of some 
physical methods of therapy.
Photodynamic therapy (PDT) is based on the appli-
cation of a non-toxic photosensitizer that accumulates 
selectively in cancer cells. Once excited by laser-emit-
ted light of appropriate wavelength, the photosensitizer 
transmits the energy to molecular oxygen with formation 
of singlet oxygen and other reactive oxygen species, 
which elicit a potent cytotoxic effect. Since the basic 
principle of PDT is different from that of the conventional 
chemotherapy, PDT has been considered an alterna-
tive approach to overcoming MDR phenotype [1, 2]. 
In fact, some studies showed that PDT is effective 
in the treatment of MDR cancer cells [1]. The cross-
resistance to chemotherapeutic drugs and several 
photosensitizers, in particular porphyrin derivatives 
has been also reported [3]. Nevertheless, in seve ral 
studies cross-resistance to PDT in MDR leukemia cells 
has not been confirmed [4]. It should be also noted that 
in MDR cancer cells the advantages of PDT treatment 
may be associated with the mechanisms other than 
directly related to the P-gp overexpression.
Jurkat/A4 cells with MDR phenotype were ob-
tained upon the treatment of human T-cell acute 
lymphoblastic leukemia Jurkat cells with the agonistic 
anti-CD95 mAb [5]. It has been demonstrated earlier 
that Jurkat/A4 cells are cross-resistant to apoptosis 
induced by a broad spectrum of clinically relevant che-
motherapeutic drugs [5, 6] and to X-ray exposure [7]. 
Since MDR of Jurkat/A4 cells involves the mechanisms 
other than P-gp mediated efflux [8], analysis of PDT 
effects in these cells undertaken in our study seems 
to be of considerable interest.
Therefore, the aim of the study was to clarify whether 
the multidrug resistant Jurkat/A4 leukemia cells pos-
sess the cross-resistance to photodynamic treatment.
MATERIALS AND METHODS
Cells. Human T-cell acute lymphoblastic leukemia 
line Jurkat was obtained from the National Collection 
of Cell Lines of R.E. Kavetsky Institute of Experimental 
Pathology, Oncology and Radiobiology (Kyiv, Ukraine). 
The Jurkat/A4 cell subline was generated earlier 
as previously described [5]. The cells were cultured 
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in RPMI-1640 medium (Sigma, USA) supplemented 
with 2 mM L-glutamine and 10% fetal calf serum (Sigma, 
USA) at 37 °C and 5% CO2. Both cultures were passaged 
every 3–4 days upon reaching maximum cell density.
Photosensitizers. 5-Aminolevulinic acid (ALA) 
and two chlorine е6 based formulations — Photolon 
(PL) (RUE Belmedpreparaty, Belarus) and its conju-
gate with gold nanospheres of 45 nm in diameter, were 
used as photosensitizers.
Photodynamic treatment and cytotoxicity. 
Cells in log-phase were treated with photosensitizers 
in Hanks’ solution without phenol red. ALA was assayed 
at concentrations 0.1 mM, 0.5 mM and 1 мМ. Cells 
were incubated with ALA for 4 h at 37 °С allowing for 
ALA conversion to protoporphyrin IX and then were 
exposed to the radiation of helium-neon laser LG-
111 at the wavelength of 633 nm with energy density 
of 25 J/cm2. Upon exposure to laser radiation, the cells 
were transferred to complete nutrient medium and 
cultured for 18 h at 37 °С. PL was assayed at 0.1 μg/mL, 
0.25 μg/mL and 0.5 μg/mL by chlorine е6. Cells were 
incubated with PL for 1.5 h, washed out thrice with non-
colored Hanks’ solution and exposed to semiconduc-
tor laser at λ = 658 nm with energy density of 1 J/cm2. 
The exposed cells were transferred to the fresh me-
dium and cultured for 18 h at 37 °С. PL-gold composite 
with gold nanoparticles concentration of 10 μg/mL was 
assayed under the same conditions as PL. Cell viability 
was assessed by trypan blue exclusion test.
Apoptosis estimation. Apoptosis in Jurkat and 
Jurkat/A4 cells was assessed by flow cytometry. 
The cells were resuspended in hypotonic lysis buffer 
containing 0.1% sodium citrate, 0.1% Triton X-100, 
5 μg/ml propidium iodide. 250 μg/ml of RNAse A was 
added to each sample, and the cells were stained 
for 15 min at 37 °C. Flow cytometry was performed 
on a BDTM FACSCalibur system (Becton Dickin-
son, USA). Forward and sideways light scattering 
provided the elimination of dead cells and debris. 
The ﬂuorescence of propidium iodide-stained cells was 
measured. The data were analyzed using CellQuest soft-
ware package (BD “Biosciences”, USA). Sub-G1 (<2N 
ploidy) cell population was considered as apoptotic. The 
net apoptosis percentage following subtraction of spon-
taneous apoptosis in non-treated cells was calculated.
Microarray analysis. The gene expression profiles 
were evaluated with Affymetrix U133A chips (Santa 
Clara, CA, USA) as previously described [9]. The pro-
tocol for processing the RNA, ampli fying and labeling 
fragments, hybridizing material on the microarray, 
and scanning was similar to the standard Affymetrix 
protocol for GeneChip® expression analysis. Expres-
sion of the genes under study in Jurkat and Jurkat/
A4 cells was compared based on our data set (MIAM-
Express Database, accession number  E-MEXP-530) 
processed with the aid of Microarray Suite software. 
Binary log ratios and fold changes were calculated 
by comparing signals in Jurkat/A4 and Jurkat cells. 
The expression data on CD3G gene encoding for T-cell 
specific membrane protein were given as internal con-
trol. The arbitrary 2-fold-change cutoff was set for our 
analysis to decide whether the gene was differentially 
expressed in Jurkat/A4 vs. Jurkat cells.
Statistical analysis. The data on cell phototoxi-
city and apoptosis were obtained in triplicate experi-
ments. t test was used for statistical analysis. A value 
of p < 0.05 was accepted as statistically significant. 
The microarray data were analyzed with the aid of Mi-
croarray Suite software.
RESULTS
ALA as well as both chlorine е6 compositions (PL and 
PL-gold composite) have been shown to be devoid 
of dark (without light) cytotoxicity (data not shown). 
The distinct concentration-dependent cell death was 
demonstrated in Jurkat cells pretreated for 4 h with 
ALA at the doses in the range of 0.1–1.0 mM followed 
by the exposure to radiation of helium-neon laser 
(Fig. 1). ALA-mediated PDT-induced cell death was 
also evident in Jurkat/A4 cells although the death frac-
tions in Jurkat/A4 cells in ALA dose range used were 
significantly lower than in the parental Jurkat cell line 
(54% vs. 80% for the maximal dose).
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Fig. 1. Percentage of cell death (a) and induced apoptosis (b) 
in Jurkat and Jurkat/A4 cells pretreated with ALA and exposed 
to laser radiation at λ = 633 nm. Cell death was estimated by try-
pan blue exclusion. Apoptosis was determined by flow cyto-
metry of propidium iodide-stained cells. Each point represents 
the means ± S.D. of triplicate samples
As shown in Fig. 2, both cell lines were also sensi-
tive to PL-mediated PDT. However, the patterns of such 
sensitivity were different. In Jurkat cells, PL-mediated 
PDT-induced cell death was clearly dose-dependent 
while in Jurkat/A4 cells the death fraction was maximal 
at 0.25 μg/mL and did not increase further with incre asing 
PL concentration. Again, as in ALA-mediated PDT tests, 
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the maximal death fraction in Jurkat cells was significantly 
higher than in Jurkat/A4 cells (77% vs. 23%).
The effects of PL as a photosensitizer were fur-
ther compared to those of PL composite with gold 
nanospheres. PDT-induced cell death in Jurkat cells 
treated with PL-gold composite exceeded that PL, but 
in Jurkat/A4 cells, the effects of PL-gold composite 
were not superior to those of PL.
Therefore, Jurkat/A4 cells proved to be less suscep-
tible to PDT-induced cell damage mediated both by ALA 
and PL applied in the form of two different preparations.
Then, the contribution of apoptosis into the over-
all Jurkat and Jurkat/A4 cell death in PDT tests was 
analyzed. As shown in Fig. 1, the general pattern 
of ALA-mediated PDT-induced apoptosis in Jurkat and 
Jurkat/A4 cells was similar with an absolute percent-
age of hypodiploid cells in both cell lines being only 
a small part of the total cell death fraction (13% vs. 
80% in Jurkat cells and 8% vs. 54% in Jurkat/A4 cells 
at 1 mM ALA). As opposed to this, the pronounced 
apoptotic effect was evident in PL-mediated PDT tests 
in Jurkat and Jurkat/A4 cells with relatively high per-
centage of apoptotic fraction making up to at least half 
of the total death fraction at the similar photosensitizer 
concentrations (Fig. 2). The treatment with PL-gold 
composite tended to decrease apoptosis percentage 
as compared with that in PL-treated cells.
To gain insight into mechanisms of the different 
PDT responsiveness, gene-expression proﬁling stu dies 
of parental Jurkat cells and resistant Jurkat/A4 cells 
were performed. The data relevant to genes involved 
in PDT sensitivity/resistance are presented in the Table. 
Both Jurkat and Jurkat/A4 cell lines showed the typi-
cal feature of T-cells: high signal intensities for CD3g. 
Among 10 genes that had been reported previously 
as been involved in sensitivity/resistance to PDT only 
FECH, NFE2L2, GPX4, LDLR, and RUNX3 were ex-
pressed in studied cells at meaningful levels. However, 
the differences in their expression between Jurkat/
A4 and parental cell line were not significant.
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Fig. 2. Percentage of cell death (a) and induced apoptosis (b) 
in Jurkat and Jurkat/A4 cells pretreated with PL or PL-gold 
nanocomposite and exposed to laser radiation at λ = 658 nm. 
Cell death was estimated by trypan blue exclusion. Apoptosis was 
determined by flow cytometry of propidium iodide-stained cells. 
Each point represents the means ± S.D. of triplicate samples. 
* p < 0.05 PL vs. PL-gold
Table. Expression of genes associated with sensitivity/resistance to PDT in Jurkat/A4 cells as compared to parental Jurkat cells*
Affime-
trix ID
Gene 
symbol Entrez gene name
Signal intensity 
from Jurkat/A4 cells
Signal 
evaluation
Fold change, Jurkat/A4 vs. Jurkat Change 
p valueBinary log ratio Folds 
203116_s_at FECH Ferrochelatase (protoporphyria) 512.8 P 0.4 1.32 0.000023402.8 P 0.2 1.15 0.094279
209735_at ABCG2 ATP-binding cassette, sub-family G (WHITE), mem-ber 2
72.5 A 0.2 1.15 0.429141
28.1 A −0.5 0.71 0.500000
201146_at NFE2L2 Nuclear factor (erythroid-derived 2)-like 2 289.5 P −0.1 0.93 0.757415295.8 P −0.1 0.93 0.500000
201106_at GPX4 Glutathione peroxidase 4 (phospholipid hydroper- 1281.8 P 0.1 1.07 0.366593918.9 P −0.3 0.81 0.981872
208711_s_at CCND1 Cyclin D1 18.3 A −1.3 0.41 0.5000009.9 A −1.2 0.44 0.145682
200953_s_at CCND2 Cyclin D2 144.3 P 1.4 2.64 0.00013116.2 P 1.5 2.83 0.001077
201700_at CCND3 Cyclin D3 801.0 P −0.2 0.87 0.9818721907.5 P 0.3 1.23 0.232549
211607_x_at EGFR Human epidermal growth factor receptor precursor 7.6 A −0.1 0.93 0.7039116.9 A 0.2 1.15 0.203871
214786_at MAP3K1 Mitogen-activated protein kinase kinase kinase 1 19.6 A 1.3 2.46 0.23254917.3 A 0.1 1.07 0.118009
205680_at MMP10 Matrix metallopeptidase 10 (stromelysin 2) 1.9 A −0.1 0.93 0.50000016.4 A 2.2 4.59 0.378880
202068_s_at LDLR Low density lipoprotein receptor (familial hyper- 132.8 P 0.5 1.41 0.105663434.2 P 0.2 1.15 0.500000
204197_s_at RUNX3 Runt-related transcription factor 3 146.0 P 0.4 1.32 0.000101181.7 P 0.6 1.52 0.002032
206804_at CD3G CD3g molecule, gamma (CD3-TCR complex) 627.4 P 0.4 1.32 0.015426664.6 P 0.1 1.07 0.500000
*Two replicate values given for each gene were obtained independently with three-month interval. In Microarray Analysis Suite software Wilcoxon’s test was 
used to generate detected calls; signal evaluation: when p < 0.05 – transcripts are present (P), when p > 0.05 – absent (A). A transcript was considered 
differentially expressed in Jurkat/A4 vs. Jurkat cells when increased or decreased more than 2.0-fold in both replicates with Log Ratio p-value threshold 
p < 0.05 for increased expression and p > 0.95 for decreased expression (one-sided Wilcoxon’s rank test) 
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DISCUSSION
PDT is a modern treatment modality that may be ad-
vantageous in therapy of some forms of cancer [10]. 
Moreover, PDT has been considered an alternative ap-
proach to overcoming MDR phenotype [2]. Neverthe-
less, the mechanisms contributing to the PDT-induced 
death of cancer cells with MDR phenotype have not 
been elucidated yet. The cross-resistance of MDR 
cells to PDT has been also the question of controversy. 
It is not known to which extent the apoptosis induction 
contributes to PDT-induced cell death.
Two different photobiologically active substances were 
assayed in our PDT study. ALA is not a photosensitizer per 
se and converts to the true photosensitizer, protopor-
phyrin IX, in the cells by the heme biosynthesis pathway. 
The tumor selectivity of ALA-mediated PDT-induced cell 
death is believed to be associated in part with the in-
creased accumulation of protoporphyrin IX in cancer cells 
due to decreased activity of ferrochelatase, a rate-limiting 
enzyme in heme biosynthesis pathway. PL represents 
the complex of chlorine е6 photosensitizer with polyvinyl 
pyrrolidone at a 1:1 ratio. Thus, the substances used here 
as photosensitizers differed in their photophysical proper-
ties, biological mechanisms, accumulation and selectivity 
patterns [11]. Therefore, it seemed informative to compare 
PDT activity in terms of cell death and apoptosis induction 
in the leukemic cells studied.
Jurkat/A4, a stable subline of Jurkat cells with 
acquired MDR phenotype, is a useful model for study-
ing the apoptotic resistance [5, 9, 12]. The previous 
studies demonstrated certain defects in realization 
of apoptosis in these MDR cells [6] while underlying 
mechanisms of such defects have not been eluci-
dated yet. Since PDT effects of both ALA and chlorine 
e6 do not seem to be associated with the mechanisms 
related to the P-gp overexpression [4, 13], it was of in-
terest to analyze PDT-induced cell death and apop-
tosis in MDR cells possessing the cross resistance 
towards the broad spectrum of chemotherapeutic 
agents and physical factors that is not presumably 
determined by P-gp dependent mechanisms [8].
Since ALA-PDT demonstrated cross-resistance 
to chemotherapy in several cell types [4, 14], it was impor-
tant to clarify whether ALA-PDT is effective in the treat-
ment of Jurkat/A4 cells with MDR phenotype. In fact, our 
findings demonstrated the cross resistance of Jurkat/
A4 cells to PDT-induced cell phototoxicity mediated 
by both ALA and PL. Nevertheless, the ratio of inferred 
photosensitizer concentrations resulting in the same 
PDT-induced cell phototoxicity in resistant Jurkat/A4 and 
parental Jurkat cells is many times less than the corre-
sponding ratios in assays with various classes of che-
motherapeutic agents [5]. Similarly, less than two-fold 
reduction of the responsiveness to ALA-mediated PDT 
was earlier found out in B-cell malignant Raji cells with 
the acquired six-fold resistance to doxorubicin [15].
We have also assayed photodynamic efficacy 
of PL nanocomposite with colloid gold taking into account 
the tropism of the colloid gold to cancer cells [16]. It was 
earlier shown that conjugation with gold nanoparticles 
increases the photodynamic effects of PL and hema-
toporphyrin in leukemic cells [17, 18]. Therefore, it was 
interesting to find out whether such activation explained 
usually by a better transportation of drugs into the treated 
cells [19] would affect the photodynamic responses 
of MDR leukemic cells. As it is seen from Fig. 2, in our 
experiments with Jurkat/A4 cells, the activity of PL-gold 
composite was not superior to that of free PL.
The mechanisms of the cell death induced by two stu-
died photosensitizers were analyzed. Whereas the con-
tribution of apoptosis in ALA-mediated phototoxicity was 
small, PL-mediated death of Jurkat and Jurkat/A4 cells 
was characterized by relatively large apoptotic fraction 
suggesting greater role of apoptosis in PL-mediated 
as compared with ALA-mediated phototoxicity.
The involvement of several genes such as FECH, 
ABCG2, NFE2L2, GPX4, CCND1, EGFR, MAP3K1, 
MMP10, LDLR, and RUNX3 into sensitivity/resistance 
to PDT has been recently proposed [20–22]. In our 
microarray study, only five genes from the list of those 
supposedly involved into PDT resistance, namely 
FECH, NFE2L2, GPX4, LDLR, and RUNX3, were ex-
pressed at meaningful levels, although the differences 
in their expression between Jurkat/A4 and parental cell 
line were not significant. Recently, cyclin D1 involve-
ment [23] was found to be relevant to the development 
of squamous cell carcinoma resistance to PDT, but 
we have not detected CCND1 expression in both Jurkat 
and Jurkat/A4 cell lines. We hypothesized that other 
D-type cyclins may substitute for cyclin D1 in leukemia 
cells under study. Indeed, both cell lines expressed 
high levels of CCND2 and CCND3. Furthermore, 
the expression of CCND2 but not CCND3 increased 
significantly in the Jurkat/A4 vs. Jurkat cells. As cy-
clin D2 is commonly overexpressed in hematological 
malignancies [24, 25], it would be intriguing to inves-
tigate the possible role of CCND2 in PDT resistance 
of leukemia cells.
To sum up, Jurkat/A4 cells with MDR phenotype 
turned out to be moderately cross-resistant to PDT-in-
duced cell death and apoptosis irrespective of whether 
ALA or PL was used as a photosensitizer. However, 
the relative contribution of apoptotic cell death into 
the overall phototoxicity of these two substances 
differs considerably. The further analysis of PDT cy-
totoxicity in susceptible and resistant leukemic cells 
may be useful for eluci dating the underlying general 
mechanisms of PDT effects and phenomenon of cross 
resistance.
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